Ballantyne G H
Section of Minimally Invasive and Telerobotic Surgery, Hackensack University Medical Center, Hackensack, New Jersey 07601, USA.
Surg Endosc. 2007 Jul;21(7):1054-62. doi: 10.1007/s00464-006-9130-7. Epub 2007 Feb 8.
The Federal Drug Administration (FDA) approved the da Vinci surgical system for all abdominal operations in July 2000. In the past 6 years, virtually all gastrointestinal operations have been accomplished using telerobotic techniques. The purpose of this review is to summarize the short-term outcomes achieved with telerobotic gastrointestinal operations.
All case series of telerobotic gastrointestinal operations identified by PubMed searches are included in this review.
Case series document the safety and efficacy of telerobotic cholecystectomy, fundoplication, Heller myotomy, gastric bypass, colectomy, gastrectomy, and pancreatectomy. The procedures were accomplished with low rates of conversion to laparoscopic operations, mortality, and morbidity. When comparison groups were available, the analysis shows that telerobotic operations required more time than the laparoscopic operations, although for telerobotic cholecystectomy and telerobotic fundoplication, this difference disappeared in 10 to 20 operations. Specific patient advantages were not identified for telerobotic operations compared with laparoscopic operations, except for a decreased esophageal perforation rate during telerobotic Heller myotomy. Surgeons benefited from the three-dimensional imaging, the handlike motions of the robotic instruments, and an ergonomically comfortable position.
All telerobotic gastrointestinal operations are feasible and can be performed with safety and efficacy. It is difficult to demonstrate patient-specific advantages of telerobotic surgery over laparoscopic operations. Nonetheless, telerobotic surgical systems offer distinct advantages to surgeons and may facilitate an increase in the number of surgeons performing advanced laparoscopic gastrointestinal operations. In addition, telerobotics offer a digital information platform that enables surgical simulation and augmented-reality surgery.
2000年7月,美国食品药品监督管理局(FDA)批准达芬奇手术系统用于所有腹部手术。在过去6年中,几乎所有胃肠手术均采用远程机器人技术完成。本综述的目的是总结远程机器人胃肠手术的短期疗效。
本综述纳入了通过PubMed检索确定的所有远程机器人胃肠手术病例系列。
病例系列证明了远程机器人胆囊切除术、胃底折叠术、贲门肌切开术、胃旁路术、结肠切除术、胃切除术和胰腺切除术的安全性和有效性。这些手术中转开腹手术率、死亡率和发病率均较低。当有可比组时,分析表明远程机器人手术比腹腔镜手术需要更多时间,不过对于远程机器人胆囊切除术和远程机器人胃底折叠术,在进行10至20例手术后这种差异消失。与腹腔镜手术相比,未发现远程机器人手术有特定的患者优势,除了在远程机器人贲门肌切开术中食管穿孔率降低。外科医生受益于三维成像、机器人器械的类手动作以及符合人体工程学的舒适体位。
所有远程机器人胃肠手术都是可行的,并且可以安全有效地进行。很难证明远程机器人手术相对于腹腔镜手术对患者有特定优势。尽管如此,远程机器人手术系统为外科医生提供了明显优势,可能有助于增加进行高级腹腔镜胃肠手术的外科医生数量。此外,远程机器人技术提供了一个数字信息平台,可实现手术模拟和增强现实手术。